Developing novel neuroprotective therapeutics to reduce brain damage after stroke.
A clinical stage drug development company developing novel therapeutics for stroke and other types of brain injuries, which are developing a "best in class" novel neuroprotective therapeutic.
There is currently a large unmet need for a safe, early intervention therapeutic that provides protection to brain cells immediately following a stroke, until the underlying cause of stroke can be diagnosed and alleviated.
It is Argenica's mission to provide a solution for this unmet need. Their aim is for ARG-007 to be administered by first responders in the field to provide neuroprotective treatment prior to a patient’s arrival at the hospital which will result in improved patient outcomes.
Ms Angus brings extensive executive managerial and company director experience in the biotechnology, biopharmaceutical, agritech and healthcare industries. She has long been involved in path to market asset development and commercialisation in these industries, notably including the clinical validation of drug therapeutics to create asset valuation uplift. Ms Angus has held Director roles in a number of ASX and NASDAQ-listed companies and as is currently a Non-Executive of Neuren Pharmaceuticals (ASX: NEU), Cyclopharm (ASX: CYC) and Imagion Biosystems (ASX: IBX), she is also a council member of Deakin University.
Additionally, Ms Angus holds a Master of Biotechnology, Bachelor of Science (Hons), and a Graduate Diploma of Intellectual Property (IP) Law. She is a registered patent attorney and a member of Australian Institute of Company Directors (AICD).
Dr Dallimore has over 20 years’ experience in both biotechnology and management consulting across Australia and the UK. She has held senior roles in management consulting as KPMG’s Australian Director of Research Engagement and Commercialisation, structuring technology commercialisation deals across a range of sectors, with a specific focus on biotechnology. Prior to this Liz held senior management roles with Ernst & Young and PricewaterhouseCoopers in technology advisory and R&D. Prior to moving into management consulting, Liz was a research scientist at the Australian Neuromuscular Research Institute (now the Perron Institute of Neurological & Translational Sciences) and the UK’s Food Standard’s Agency.
Dr Dallimore is also a Non-Executive director of the Chamber of Commerce and Industry WA and AusBiotech, as well as and Industry Advisor to the Telethon Kids Institute’s Innovation and Commercialisation Committee and member of the Stan Perron Charitable Foundation’s Health Research Advisory Panel advising on child health research funding.
Dr Dallimore holds a PhD in Neuroscience jointly completed at Oxford University and the University of Western Australia, an MBA from the Australian Graduate School of Management, and is a Member of the Australian Institute of Company Directors.
Mr Geoff Pocock has over 20 years’ experience in commercialisation, corporate finance and strategy, and has specialised in the commercialisation and funding of early stage research projects from universities, and taking spin out companies to successful ASX listings. Geoff has served on the Board of a number of listed and unlisted companies, and he is currently a non Executive Director of EMVision Medical Devices Ltd (ASX:EMV). He is also the founder and former Managing Director of Hazer Group Limited (ASX: HZR), which was spun out of The University of Western Australia in 2010 and listed on ASX in 2015. Geoff has tertiary qualifications in Chemistry, Law and Applied Finance and is a Member of the Australian Institute of Company Directors.
Ms Liddy McCall has over 20 years’ experience as a founder, investor and in executive management. She co-founded venture capital group Yuuwa with key roles over its portfolio of early stage startups in biotechnology, agritech and IT. Liddy is successful entrepreneur including as co-founder and named inventor on the therapeutic patents commercialised by Dimerix Limited (ASX:DXB); co-founder of the iCeutica Group (acquired) and Argus Biomedical Pty Ltd (acquired), co-founder of The Tailor Made Spirits Company Limited (West Winds Gin) and Cowaramup Distillery & Tavern. She is involved in a range of healthcare businesses and programs.
Ms McCall was an Associate Director, Macquarie Bank focusing on mergers and acquisitions. Ms McCall has been admitted as a barrister and solicitor in various Australian jurisdictions and has degrees in finance, law and management. Ms McCall is on the Board of various private groups in property and funds management, data management, and fast-moving-consumer-goods (FMCG).
Non-Executive Director
Mr Terry Budge was a Director of Aspen Group Limited from 6 May 2005 to 23 November 2012. He was also Chancellor of Murdoch University from 2006 to 2013 (appointed to Senate 1 June 2004). Mr Budgeholds a Bachelor of Economics from Monash University and is a Graduate of the Advanced ManagementProgram from Harvard Business School. He is also a Graduate and Fellow of the Australian Institute of Company Directors and a Senior Fellow of FINSIA. He is currently a non-executive director and Chairman of the Audit Committee of Westoz Investment Company Ltd (ASX:WIC).
Ms Waldon has diverse accounting, capital markets and corporate governance experience in Australia and the UK and is currently Company Secretary of EMVision Medical Devices Ltd (ASX:EMV) and a number of unlisted companies. Ms Waldon was Company Secretary of Hazer Group Limited (ASX: HZR). Ms Waldon was a director of Moko Social Media Ltd (ASX:MKB) when voluntary administrators were appointed to the company on 31 May 2017.
